PuSH - Publikationsserver des Helmholtz Zentrums München

Finan, B. ; Clemmensen, C. ; Müller, T.D.

Emerging opportunities for the treatment of metabolic diseases: Glucagon-like peptide-1 based multi-agonists.

Mol. Cell. Endocrinol. 418, 42-54 (2015)
DOI PMC
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Obesity is a pathogenic gateway to the metabolic syndrome and the complications thereof, thus interventions aimed at preventing or reversing the metabolic derangements underlying obesity hold great therapeutic promise. However, the complexity of energy balance regulation, combined with the heterologous pathophysiology of human obesity, renders effective medicinal intervention very difficult. Indeed, the search for the silver bullet in anti-obesity medicines has been laden with drugs of underwhelming efficacy and unacceptable side effects. This can partly be the consequence that many of these drug interventions have been historically directed at single molecular targets. New multi-molecular combination therapies have shown promising clinical outcomes in terms of weight loss, yet multi-functional single molecules may offer even more advantages than adjunctive co-treatments. Single molecules with integrated activities derived from multiple hormones involved in the physiological control of metabolism have emerged as one of the more promising candidates for reversing obesity. The inclusion of glucagon-like peptide-1 (GLP-1) as one of the constituents is a unifying factor amongst the majority of these unimolecular multi-agonists. The scope of this review is to summarize the current preclinical and clinical landscape of GLP-1-based therapies, focusing on combinatorial therapies with a particular emphasis on single molecule compounds displaying multi-agonist properties.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Korrespondenzautor
Schlagwörter Amylin ; Diabetes ; Estrogen ; Gastrin ; Glucagon ; Glucagon-like Peptide-1 ; Glucose-dependent Insulinotropic Polypeptide: Glucagon-like Peptide-2 ; Obesity ; Oxyntomodulin ; Polypharmacy
ISSN (print) / ISBN 0303-7207
e-ISSN 1872-8057
Zeitschrift Molecular and Cellular Endocrinology
Quellenangaben Band: 418, Heft: , Seiten: 42-54 Artikelnummer: , Supplement: ,
Verlag Elsevier
Verlagsort Shannon
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Diabetes and Obesity (IDO)